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A B S T R A C T
Background: Systematically obtained data on antiretroviral (ARV) resistance in Colombia are lacking.
Local estimates of resistance are needed to guide testing, therapy, and policy.
Methods: A cross-sectional study was performed in ARV-naı¨ve individuals and in patients with ﬁrst ARV
failure. Genotypic resistance testing was performed using Viro-seq. Predicted success to ﬁrst- and
second-line regimens recommended by the Colombian HIV treatment guidelines was estimated.
Results: One hundred and three naı¨ve and 77 experienced patients were included. For naı¨ve patients,
resistance mutations were detected in 5.8%, with the most common mutations being 103N (n = 5; 4.9%)
and 184 V (n = 3; 2.9%). CD4 count <200 cells/mm3 (p = 0.04) and Centers for Disease Control and
Prevention (CDC) category C (p = 0.004) were associated with primary resistance. For experienced
individuals, regimens were non-nucleoside reverse transcriptase inhibitor (NNRTI)-based in 57.1%,
protease inhibitor (PI)-based in 14.3%, boosted PI-based in 26.0%, and nucleoside reverse transcriptase
inhibitor (NRTI)-based in 2.6% of the cases. Resistance mutations were found in 66 patients (85.7%) with
failure. The most common mutations were 184 V (n = 48; 62.3%), 103N (n = 37; 48.1%), G190A/S (n = 9;
11.7%), and L90 M (n = 9; 11.7%). Twelve percent had thymidine analogue mutations (TAMs) but only 1%
had more than 1 TAM. The predicted success of regimens recommended by the Colombian guidelines
was 95% for naı¨ve patients and 84% for experienced patients. Genotyping could increase the success rates
to 100% and 94%, respectively.
Conclusions: The frequency of primary HIV resistance in Colombia is similar to estimates from other
countries in Latin America. CD4 count and CDC category C may allow identiﬁcation of most of the naı¨ve
patients who would beneﬁt from resistance testing. Resistance testing could favorably impact therapy
modiﬁcation in about 5% and 10% of naı¨ve and experienced patients, respectively.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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journa l homepage: www.e lsev ier .com/ locate / i j id1. Introduction
There are about 2 million people living with HIV/AIDS in Latin
America and the Caribbean, with 120 000 new cases and 70 000
estimated deaths in 2007 for the entire region.1 Located in the
northwestern corner of South America, Colombia has an estimated
HIV prevalence rate of 0.6% and approximately 170 000 people
living with HIV.2 HIV/AIDS is the third most important cause of
death in people between 15 and 49 years of age in Colombia,
surpassed only by homicide, accidents, and other violent deaths.3* Corresponding author. Tel.: +1 404 6164634; fax: +1 404 8809305.
E-mail addresses: cdiazgr@emory.edu, cdiazgr@yahoo.com (C.A. DiazGranados).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.05.006The availability of antiretroviral (ARV) therapy has changed the
natural history of HIV infection dramatically,4 and the rapid scale-
up of ARV in resource-limited settings is an international priority.5
However, as ARV therapy is expanded and rolled out, resistant
viruses emerge. HIV resistance is considered a rising worldwide
problem, and the World Health Organization (WHO) recommends
HIV resistance surveillance as a component of ARV rollout
programs.6 The Colombian Obligatory Health Plan (Plan Obliga-
torio de Salud, POS), established by law in 1993, includes HIV/AIDS
on its list of diseases that require high-cost treatments. This plan
mandates the free provision of ARV therapy by Health Promoting
Entities (Entidades Promotoras de Salud, EPS)7 under the General
Social SecurityHealth System (SistemaGeneral de Seguridad Social
en Salud, SGSSS). As a result, 72% of the total ARV treatments inses. Published by Elsevier Ltd. All rights reserved.
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estimated that 21 000 patients were receiving ARV therapy in
Colombia, covering approximately 38% of those in need.2 The
restrictions in ARV therapy coverage result in part from
the limitations in detection and diagnosis of HIV infection in the
country. In fact, the Colombian government has estimated that
78.5% of the patients who are known to be HIV infected and who
are afﬁliated to the SGSSS are receiving ARV treatment.8 The
efﬁcacy of ARV therapy in Colombia has recently been evaluated9
in a study that reported suboptimal virologic response rates. The
authors postulated as one possible explanation a high frequency of
circulating HIV-resistant viruses in the country.9 Unfortunately,
despite years of ARV utilization, no systematic studies evaluating
HIV resistance have been performed in Colombia.
Country-speciﬁc HIV resistance knowledge is needed to guide
ARV therapy and resistance testing policies.10 HIV-resistant viruses
can be transmitted and may affect the efﬁcacy of ARV medica-
tions.11 Guidelines from resource-rich countries recommend the
performance of HIV resistance testing prior to the initiation of ARV
therapy and whenever ARV therapy failure occurs.12–14 However,
resistance testing at the individual level may not be feasible in
settings with signiﬁcant resource limitations. As a result, theWHO
recommends resistance testing at a population level in these
settings.5,6 Colombia is a country with intermediate resource
limitations. National HIV/AIDS guidelines recommend resistance
testing at a patient level only beyond the ﬁrst ARV therapy failure,
with decisions regarding ARV initiation and ﬁrst ARV failure based
solely on suggested regimens without the guidance of resistance
testing.15
The objectives of the current study were: (1) to determine the
prevalence and predictors of resistance in therapy-naı¨ve indivi-
duals and in patients with ﬁrst regimen failure in Colombia; (2) to
describe the patterns of resistance in therapy-naı¨ve individuals
and in patients with ﬁrst virologic failure; and (3) to calculate the
rates of predicted success of ﬁrst- and second-line regimens
recommended by the Colombian HIV treatment guidelines.
2. Methods
We performed a prospective cross-sectional study that
included adult patients with conﬁrmed HIV infection who were
unexposed to ARV therapy (naı¨ve group) and patients with current
ARV exposure diagnosed with ﬁrst regimen virologic failure (ﬁrst
failure group). Virologic failure was deﬁned according to the
Colombian HIV guidelines15 as two consecutive suboptimal viral
load levels (detectable viral load in those with a therapy duration
of 6 months, or viral load not decreased by at least 1 log per
month in those with a therapy duration of <6 months) despite an
attempt to optimize adherence, tolerance, and pharmacokinetic
barriers. The Colombian HIV guidelines recommend repeating HIV
viral loadwithin 2months once one viral load has been determined
to be suboptimal, allowing for classiﬁcation of patients as virologic
failure or not within a follow-up period of 6 months or less.
Patients failing a regimen for more than 6 months were excluded
from the study. This was done to avoid including patients with
prolonged virologic failure who were persistently taking a
suboptimal regimen and therefore had higher risk for resistance
mutation accumulation. Additionally, the viral load prior to
enrollment was required to be 2000 copies. Viral load was
performed using Versant bDNA 3.0 (Bayer), LCx HIV (Abbott), or
Amplicor Monitor v1.5 (Roche) according to the preference of the
participating institutions. A recent study showed good correlation
and concordance of these three techniques in a sample of
Colombian patients.16
We includedHIV clinics from six regions of the country (Bogota´/
Cundinamarca, Valle del Cauca, Antioquia, Atla´ntico/Bolı´var,Santander, and Caldas/Risaralda) with the highest numbers of
estimated HIV cases.17 Eligible patients were sampled by
convenience according to regional number of HIV cases, so that
the proportion of cases included by region would reﬂect the
proportion of cases contributed by that region to the total number
of HIV cases in Colombia. Based on previous studies in the Latin
American region,10 we assumed a 6% prevalence of primary
resistance for the purpose of sample size calculation. Using a
margin of error of 5%, we calculated a target sample size of at least
87 naı¨ve patients to be enrolled in the study.
Genotypic resistance testing was performed at a central
laboratory (Centro Internacional de Entrenamiento e Investiga-
ciones Me´dicas (CIDEIM), Cali, Colombia) using Viro-seq (Celera
Diagnostics, Alameda, CA, USA) and following manufacturer
instructions, as described elsewhere.18
For both groups, demographic, behavioral, and clinical variables
were collected and resistance patterns and frequencies were
described. Categoric variables included: gender, CD4 count
category (below 200 cells/mm3 or not), Centers for Disease Control
and Prevention (CDC) classiﬁcation category,19 presumedmechan-
ism of transmission, history of foreign travel, history of sexually
transmitted infections (STI), and presence of reverse transcriptase
(RT) or/and protease inhibitor (PI) mutations. Numeric variables
included: age, number of sexual partners during previous 5 years,
viral load, CD4 count, and presumed time at risk. Additional
variables for patients failing therapy included: tolerance, adher-
ence according to the simpliﬁed medication adherence ques-
tionnaire (SMAQ),20 history of medication supply failure, and type
of failing regimen (based on the third component of the regimen
and according to the inclusion or not of generic medications;
regimens using generic medications were classiﬁed as pre-
qualiﬁed or not according to the WHO pre-qualiﬁcation list
(http://apps.who.int/prequal/); regimens that did not include
generics were classiﬁed as ‘innovator medications only’).
Numeric variables were summarized as medians and ranges
and categoric variables as frequencies. Predictors of resistance
were explored by bivariate analysis using Fisher’s exact test or the
Chi-square test when appropriate for categoric variables and the
Wilcoxon rank sum test for numeric variables. SAS software
version 9.2 (Cary, NC, USA) was used for the analyses. p-Values of
0.05 were considered signiﬁcant.
For the estimation of the predicted success rates to ﬁrst- and
second-line regimens recommended by the Colombian guidelines,
we calculated the mutation score for each regimen component
using the HIVdb genotypic resistance interpretation algorithm
of Stanford University (http://hivdb.stanford.edu/index.html)
according to the genotyping results for each patient. Each
component contained in a regimen recommended by the
Colombian guidelines was classiﬁed as ‘active’ if its mutation
score was less than 30 (low level resistance if any) or ‘inactive’ if its
mutation score was 30 or more. Regimens recommended were
classiﬁed as having or not having predicted success depending on
the number of ‘active’ components included in the regimen. If the
regimen contained at least three ‘active’ components, then the
regimen was classiﬁed as having predicted success. If the regimen
contained fewer than three ‘active’ components, it was classiﬁed as
not having predicted success. Because the guidelines recommend
zidovudine (AZT)–lamivudine (3TC)–efavirenz as the preferred
ﬁrst-line regimen, all resistance proﬁles of therapy-naı¨ve patients
were evaluated to determine the predicted success of this
combination. For second-line regimens, we estimated the pre-
dicted success of the regimens recommended by the Colombian
guidelines (Table 1) according to the failing regimen.15
The study was approved by the ethics committees of
participating institutions. A written informed consent was
required for patient enrollment.
Table 1
Second-line regimens recommended by the Colombian HIV/AIDS guidelines
Failing regimen Recommended second-line regimen
AZT (or D4T) + 3TC + efavirenz (or nevirapine) ABC + DDI + (fosamprenavir  ritonavir or saquinavir–ritonavir or lopinavir–ritonavir or atazanavir  ritonavir)
AZT (or D4T) + 3TC + PI ABC + DDI + efavirenz (or nevirapine)
DDI + 3TC + efavirenz (or nevirapine) AZT (or D4T) + ABC + (fosamprenavir  ritonavir or saquinavir–ritonavir or lopinavir–ritonavir or atazanavir  ritonavir)
DDI + 3TC + PI AZT (or D4T) + ABC + efavirenz (or nevirapine)
DDI + D4T + PI 3TC + ABC + efavirenz (or nevirapine)
DDI + D4T + efavirenz (or nevirapine) 3TC + ABC + (fosamprenavir  ritonavir or saquinavir–ritonavir or lopinavir–ritonavir or atazanavir  ritonavir)
AZT – 3TC – ABC 3TC + (D4T or DDI) + efavirenz (or nevirapine) + lopinavir–ritonavir
AZT, zidovudine; D4T, stavudine; 3TC, lamivudine; ABC, abacavir; DDI, didanosine; PI, protease inhibitor.
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A total of 180 patients were included, 103 in the naı¨ve group
and 77 in the ﬁrst failure group. Characteristics of both groups are
presented in Table 2. The frequency of resistance for the naı¨ve
group was 5.8% (95% conﬁdence interval (CI) 1.3–10.3%) and the
most common mutations encountered were K103N (ﬁve patients,
4.9%) and M184 V (three patients, 2.9%). Mutations T215Y, P225H,
andM46Lwere found once each (1.0%). Three naı¨ve patients (2.9%)Table 2





Categoric variables n (%) n (%)
Male gender 85 (82.5) 59 (75.3) [76.6]
History of STI 31 (30.1) 19 (25.3) [24.7]
Presumed mechanism of transmissiona
MSM 56 (54.9) 37 (48.7)
Heterosexual 46 (45.1) 39 (51.3)
Other 0 (0) 2 (2.3)b [2.6]
CDC category C 26 (25.2) 29 (37.7)
CD4 count <200 cells/mm3 42 (40.8) 41 (54.6) [53.2]
Prevalence of resistance 6 (5.8) 66 (84) [85.7]
Numeric variables Median (range) Median (range)
Age 34 (18–59) 39 (23–68)
Number of sexual partners
(last 5 years)
3 (0–250) 1 (0–20)
Number of STI last 5 years 0 (0–5) 0 (0–2)
CD4 count (cells/mm3) 240 (7–837) 118 (4–573)
Viral load 57 858
(2384 to >750 000)
16 391
(1600 to >500 000)
STI, sexually transmitted infection; MSM, men who have sex with men; CDC,
Centers for Disease Control and Prevention.
a Data missing for one patient in each group.
b Patients with more than one possible mechanism of transmission.
Table 3
Predictors of primary resistance
Resistance N = 6 No resistance N = 97 p-Valuea
Categoric variable n (%) n (%)
CD4 count <200 cells/mm3 5 (83) 37 (38) 0.04
CDC category C 5 (83) 21 (22) 0.004
Foreign travel 2 (33) 11 (11) 0.17
Numeric variable Median (range) Median (range)
Number of sexual partners (5 years)b 5.5 (1–20) 2 (0–20) 0.13
Number of STI (5 years)b 0.5 (0–2) 0 (0–2) 0.17
CD4 count (cells/mm3) 105 (48–282) 243 (7–837) 0.08
CDC, Centers for Disease Control and Prevention; STI, sexually transmitted
infection.
a Fisher’s exact test for categoric variables, Wilcoxon rank sum test for numeric
variables.
b Excluding extreme values (>95th percentile).had mutations to more than one class: two had mutations K103N
and M184 V and one had mutations K103N, M184 V, P225H, and
T215Y. Three naı¨ve patients had single classmutations: two had an
isolated K103N mutation and one had an isolated M46L mutation.
The median time at risk in this group was 6 years. We found a
statistically signiﬁcant association between CD4 count below
200 cells/mm3 and CDC category C with the presence of primary
resistance (Table 3).
In the ﬁrst failure group, the most common regimen was non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based, with
AZT–3TC–efavirenz being the most common components
(Table 4). Eighty-eight percent of the patients reported good
tolerance and 70%were classiﬁed as adherent to therapy according
to the SMAQ. Mutations to at least one class were found in 66
patients (85.7%, 95% CI 78–93%) overall. Of 44 patients failing an
NNRTI-based regimen, 41 (93.2%) showed resistance mutations
compared to 25 of 33 (76%) patients failing a non-NNRTI-based
regimen (p = 0.04). Nucleoside reverse transcriptase inhibitor
(NRTI) mutations were signiﬁcantly more common in patients
failing an NNRTI-based regimen (p = 0.01). Only one patient failing
an NNRTI-based regimen was diagnosed with 2 thymidine
analogue mutations (TAMs). The median age of patients with
resistance mutations was higher than that of patients without
resistance (40 years vs. 35 years, p = 0.04).Mutationswere found in
10 of 11 patients (90.9%) reporting a history of medication supply
failure. There was no association between generic components in a
regimen and presence of resistancemutations. Table 5 describes inTable 4
Antiretroviral regimen types and regimen components in
patients with ﬁrst regimen failure
Type of ARV regimen n (%)
NNRTI 44 (57.1)
Boosted PI 20 (26.0)
Non-boosted PI 11 (14.3)
NRTI 2 (2.6)
Innovator medications only 29 (38.2)
Non-prequaliﬁed generic medication 25 (32.9)
Prequaliﬁed generic medication 22 (28.9)












ARV, antiretroviral; NNRTI, non-nucleoside reverse transcriptase
inhibitor; PI, protease inhibitor, NRTI, nucleoside reverse
transcriptase inhibitor; AZT, zidovudine; 3TC, lamivudine;
LPV; lopinavir; RTV, ritonavir; D4T, stavudine; IDV, indinavir;
ABC, abacavir; ATZ, atazanavir.
Table 5







NRTI 52 (67.5) 35 (79.5) 15 (48.4)a
NNRTI 48 (62.3) 37 (84.1) 10 (32.3)
PI 22 (28.6) 6 (13.6) 16 (51.6)
1 class 66 (85.7) 41 (93.2) 23 (74.2)
2 classes 49 (63.6) 33 (75) 15 (48.4)
3 classes 7 (9.1) 3 (6.8) 3 (9.7)
NRTI
M184V 48 (62.3) 33 (75) 13 (41.9)
D67N 1 (1.3) 1 (2.3) 0 (0)
T69D 2 (2.6) 1 (2.3) 1 (3.2)
T69N 2 (2.6) 2 (4.6) 0 (0)
69ins 1 (1.3) 0 (0) 1 (3.2)
K70R 3 (3.9) 3 (6.8) 0 (0)
T215I 1 (1.3) 1 (2.3) 0 (0)
T215Y/F 6 (7.8) 4 (9.1) 2 (6.4)
K219E/Q 1 (1.3) 1 (2.3) 0 (0)
L74V 6 (7.8) 4 (9.1) 2 (6.4)
L74I 1 (1.3) 1 (2.3) 0 (0)
V75A 1 (1.3) 1 (2.3) 0 (0)
TAM 9 (11.7) 7 (15.9) 2 (6.4)
2 TAM 1 (1.3) 1 (2.3) 0 (0)
NNRTI
K103N 37 (48.1) 29 (65.9) 7 (22.6)
G190A/S 9 (11.7) 6 (13.6) 3 (9.7)
Y181C 5 (6.5) 4 (9.1) 1 (3.2)
P225H 4 (5.2) 4 (9.1) 0 (0)
Y188H/L 4 (5.2) 4 (9.1) 0 (0)
K101E 3 (3.9) 1 (2.3) 2 (6.4)
V106A 1 (1.3) 1 (2.3) 0 (0)
V106M 1 (1.3) 1 (2.3) 0 (0)
V179D 1 (1.3) 1 (2.3) 0 (0)
V108I 1 (1.3) 0 (0) 1 (3.2)
A98G 1 (1.3) 0 (0) 1 (3.2)
PI
D30N 6 (7.8) 0 (0) 6 (19.4)
G48V 1 (1.3) 0 (0) 1 (3.2)
I50L 1 (1.3) 0 (0) 1 (3.2)
M46I 3 (3.9) 0 (0) 3 (9.7)
V82A 4 (5.2) 1 (2.3) 3 (9.7)
I84V 2 (2.6) 1 (2.3) 1 (3.2)
I54V 2 (2.6) 0 (0) 2 (6.4)
L90M 9 (11.7) 2 (4.6) 7 (22.6)
Results are n (%).
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor; TAM, thymidine analogue mutations.
a p = 0.01 when compared to patients failing NNRTI.
Table 6
Suggested expanded indications for genotype resistance testing for the country of
Colombia
Antiretroviral-naı¨ve individuals
Patients with CD4 count below 200 cells/mm3a
Patients classiﬁed as CDC category Ca
Patients with ﬁrst regimen failure
PI-based failing regimen
Patients with advanced failures (beyond ﬁrst regimen failure)b
CDC, Centers for Disease Control and Prevention; PI, protease inhibitor.
a Alternatively these patients may be considered candidates to initiate PI-based
therapy.
b This indication is recommended in the current Colombian HIV guidelines.
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regimen failure.
The predicted success rate of regimens recommended by the
Colombian guidelines was 95% for naı¨ve patients and 84% for
experienced patients. Based on currently available ARVs in
Colombia, genotyping could increase the predicted success rates
to 100% in naı¨ve individuals and 94% in those with ﬁrst regimen
failure.
4. Discussion
The frequency of HIV resistance in ARV-naı¨ve individuals in
Colombia is similar to ﬁgures from other areas in Latin America,
which have reported primary resistance rates of 1.8–6.6%.21–26 A
worldwide surveillance program (Worldwide analysis of resis-
tance transmission over time of chronically and acute infected HIV
patients; WATCH) found that the rate of resistance (to any drug)
among treatment-naı¨ve individuals was 6.4% in Latin America.10
These estimates are lower than those reported for many areas in
North America.23,27We believe that our sample is representative of
the general Colombian population of naı¨ve patients because of ourmethod of sampling and because the clinical and demographic
characteristics of our patients are very similar to those reported in
HIV reports for the country of Colombia.2,17 Our ﬁnding is against
the hypothesis suggesting that high levels of resistance may
explain the suboptimal virologic response estimated recently in a
cohort of ARV therapy in Colombia.9 Therefore, the low response
rate observed in that study may be secondary to other factors,
including the use of suboptimal regimens, limited expertise from
HIV providers in Colombia, limited patient adherence, and erratic
supply of medications. The Colombian government has since lead a
multi-sector response to optimize HIV management. The recently
approved Colombian guidelines for the management of HIV/AIDS15
have addressed issues of provider expertise and regimen optimiza-
tion and adherence, recommending aminimumlevel of expertise by
HIV providers, the use of regimens with very high expected success
rates, and the establishment of adherence programs in every HIV
clinic in the country. Additionally, the government of Colombia has
since instituted a nationwide programmatic management model
that addresses, among many other things, the issue of consistent
medication supply to patients.28 Given these nationwide initiatives,
a newstudyevaluating current ratesof optimalvirologic response in
Colombia is desirable.
Acknowledging the need for larger conﬁrmatory studies, we
believe that our estimates may be used by policy makers to deﬁne
research priorities and to cautiously guide the use of resistance
testing in this middle-income country. Given the relatively low
frequency of resistance in naı¨ve individuals, systematic testing of
HIV resistance before therapy initiation may not be justiﬁed yet,
but further studies and surveillance should be continued because
resistance rates are expected to rise as ARV use is expanded. Our
analysis suggests that the majority of patients with primary
resistance have advanced disease (category C of CDC classiﬁcation
or CD4 count below 200 cells/mm3). Other studies done in Latin
America have not found this association.26 Our ﬁnding also appears
to be inconsistent with previous reports that have shown that the
frequency of resistance is higher in recently infected individuals.29
However, it is likely that our study included predominantly
chronically infected patients and therefore it cannot be compared
to studies that have included patients with recent HIV infection.
We believe that a possible explanation for our observation is that
patients with advanced disease may have had more opportunities
for re-infection with a resistant virus strain if they continued to
engage in high-risk behaviors. In other words, duration of HIV
infection may be a surrogate marker of time at risk for re-infection
with potentially resistant strains. This is also suggested by the
trend we found for the association between number of sexual
partners and number of STIs and resistance in naı¨ve patients.While
clearly not deﬁnitive, our data support the use of genotype
resistance testing for naı¨ve patients with CD4 cell counts below
200 cells/mm3 or for those who are classiﬁed as CDC category C
who are going to initiate ARV therapy (Table 6). Alternatively,
patients with these criteria may be considered candidates for
boosted-PI rather than NNRTI-based therapy.
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was, as expected, high, and similar to that reported in other
studies.24,27 In general, the presence ofmultiple TAMs is of concern
in patients failing ﬁrst-line therapy in settings where second-line
ARV options are limited.27,30 This is particularly problematic in
settings where viral load monitoring is done infrequently,
potentially allowing the accumulation of resistance mutations
when patients continue a non-suppressive regimen.5 The fre-
quency of TAM mutations in our study was 11.7%, but multiple
TAMs were found in only 1.3% of individuals with ﬁrst regimen
failure. This suggests that virologic failures can be diagnosed
relatively early with the recommended monitoring strategy of the
current Colombian HIV guidelines (viral load testing at 6-month
intervals for those patients with optimal viral load and within 2
months after detection of ﬁrst suboptimal viral load). Because of
the low frequency of multiple TAMs, second-line regimens
recommended by the Colombian HIV guidelines have an accep-
table predicted success rate, higher than that estimated in other
resource-limited countries.30 This difference may be partially
explained by the fact that we excluded patients with virologic
failure of more than 6 months duration. Interestingly, the majority
of the guideline regimens classiﬁed as not having predicted success
(57%) in our study resulted from the selection of an NNRTI with
double NRTI as second-line regimen in patients failing PI-based
regimens who had NNRTI resistance detected by genotype.
Therefore, it seems prudent to consider genotype resistance
testing in Colombian patients failing ﬁrst ARV therapy when the
failing regimen is PI-based (Table 6), awaiting larger studies and
surveys. An important limitation of second-line regimens in
Colombia is the unavailability of tenofovir in the Colombian
markets. If tenofovir was available for use, the estimated predicted
success rate of a second-line regimen selectedwith genotype could
increase from 94% to 99%. Once tenofovir becomes available in
Colombian markets, the HIV guidelines would need to be updated
to introduce this medication as an alternative in patients with
failing ARVs and possibly as a component of ﬁrst-line regimens as
well, depending on acquisition cost and other considerations.
Our study has several limitations. The relatively small overall
sample and the few patients with resistance in the naı¨ve group
impact the precision of our estimates and introduce the possibility
of random errors. Therefore, larger studies should be carried out to
conﬁrm our ﬁndings. We also believe that there may be a selection
bias for the treatment experienced group given the high frequency
of NNRTI resistance encountered in patients failing a PI-based
regimen (32%), clearly beyond that expected based on our ﬁndings
in the naı¨ve group. This suggests that some patients considered
eligible for the study because of presumptive ﬁrst ARV failure were
instead having more advanced failures and likely had been
exposed in the past to regimens containing NNRTIs. This would
overestimate the presence of resistance mutations and under-
estimate the predicted efﬁcacy of the regimens proposed by the
Colombian guidelines. In an attempt to clarify this, we contacted
the primary providers who included patients as ‘ﬁrst therapy
failure’ for whom genotyping revealed resistance to NNRTI but
were exposed to PI (therefore having no history of NNRTI
exposure). All these providers stated that to the best of their
knowledge the patients had not been previously exposed to
antiretroviral medications. If a possible bias did not result from
provider knowingly enrolling ineligible patients, it may have still
resulted from patients providing inaccurate and misleading
information to their treating physicians. We cannot determine
whether the chain of trust for information accuracy was
compromised at any level, and only further studies will allow
clariﬁcation of this ﬁnding. Our estimates of predicted success
rates are not basedon longitudinal data butona somewhat arbitrary
deﬁnition that uses a single time-point genotypic resistanceinterpretation.31 Some patients meeting our deﬁnition of predicted
success might have not responded if followed longitudinally, and
some patients not meeting our deﬁnition might have actually
respondedwhen followed over time. Our study did not discriminate
between recent infections and chronic infections in the ARV-naı¨ve
sample. Given that the average time at risk reported by participants
was prolonged (6 years),we believe that themajority of the patients
included inournaı¨ve groupwere in fact chronically infected. Finally,
our study did not include phylogenetic HIV analysis. However, prior
studies have indicated that the predominant HIV viruses circulating
in Colombia belong to serotype B.32,33
In conclusion, the frequency of resistance before therapy
initiation in Colombia is similar to estimates from other countries
in Latin America. In naı¨ve individuals, CD4 count and CDC category
Cmay allow identiﬁcation of most of the naı¨ve patients whowould
beneﬁt from resistance testing. Genotype resistance testing could
favorably impact therapy modiﬁcation in about 5% and 10% of
naı¨ve and experienced patients, respectively. These estimates may
be used by local policy makers to deﬁne the role of resistance
testing in Colombian patients infected with HIV.
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